This study evaluates pre-analytical factors affecting circulating tumor deoxyribonucleic acid (ctDNA) analysis in breast cancer that not spread beyond the breast and or lymph nodes (early and locally advanced). ctDNA refers to freely circulating tumor DNA fragments found in the blood plasma. Pre-analytical factors such as blood collection tubes, delays in separation of plasma, centrifugation speeds, storage conditions, shipping and DNA extraction methods can all affect ctDNA measurements. Inappropriate processing can cause breaking down of the membrane (lysis) of peripheral blood cells that release background wild-type DNA and may also cause degradation of circulating tumor-specific DNA fragments. Both mechanisms will dilute levels of ctDNA in plasma and make it more difficult to detect. Evaluating the pre-analytical factors of the collection of blood and left over tissue samples for the research of cancer may help researchers to evaluate the impact of the blood collection/processing and long-term storage from patients with locally advanced breast cancer.
PRIMARY OBJECTIVES: I. To evaluate the impact of blood collection/processing. II. To evaluate the impact of long-term storage of plasma and extracted DNA. OUTLINE: This is an observational study. Patients undergo blood sample collection throughout the study. Patients also undergo collection of leftover tissue samples from standard of care (SOC) procedures and have medical records reviewed.
Study Type
OBSERVATIONAL
Enrollment
114
Undergo blood and leftover tissue sample collection
Medical records are reviewed
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Change in tumor specific circulating tumor deoxyribonucleic acid (ctDNA) levels
Will be measured as tumor fraction (%), using TARgeted DIgital Sequencing (TARDIS).
Time frame: Baseline to 5 years
Change in total cell-free DNA concentration
Will be measured in genome copies/ml of plasma, using the Quality Assessment (QA) assay.
Time frame: Baseline to 5 years
Change in total cell-free DNA fragment size profile
Will be measured as % fragmented, using the Quality Assessment (QA) assay.
Time frame: Baseline to 5 years
Change in tumor-specific circulating tumor deoxyribonucleic acid (ctDNA) fragment size profile
Will be measured as average fragment size, using TARgeted DIgital Sequencing (TARDIS).
Time frame: Baseline to 5 years
Background error rate
Will be measured as errors per bp sequenced, measured using TARgeted DIgital Sequencing (TARDIS).
Time frame: Baseline to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.